Literature DB >> 11760398

A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome.

R Tunç1, A Uluhan, M Melikoğlu, Y Ozyazgan, H Ozdoğan, H Yazici.   

Abstract

OBJECTIVE: Patients with ulcerative colitis (UC) and Crohn's disease (CD) were not represented in the diseased controls group that had been utilised in the development of the International Study Group (ISG) criteria for the diagnosis of Behçet's syndrome (BS). Having similar features, both of these conditions can pose problems in the differential diagnosis of BS. Moreover, there has been a recent awareness of coexistence of BS and familial Mediterranean fever (FMF). The aim of this study was to reassess the performance of ISG criteria among patients with BS and other rheumatological conditions, specifically including those with CD, UC, and FMF.
METHODS: 302 consecutive patients with BS and 438 patients with other rheumatological conditions were surveyed for the presence or absence of the features of BS by means of a standard form which had been prepared according to ISG criteria. All control patients with a history of oral ulcer had a pathergy test and an eye examination by an experienced ophthalmologist with a slit lamp. The sensitivity and specificity of the ISG criteria were calculated.
RESULTS: Seven of 302 patients with BS (2%) did not fulfill the ISG criteria while 5 of 438 controls (1%) fulfilled the ISG criteria.
CONCLUSION: In this study ISG criteria performed well in correctly classifying BS. Further specificity studies might be considered in CD.

Entities:  

Mesh:

Year:  2001        PMID: 11760398

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

Review 1.  Behçet's syndrome: an update.

Authors:  Hasan Yazici
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

2.  Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis.

Authors:  R Karasawa; M S Kurokawa; K Yudoh; K Masuko; S Ozaki; T Kato
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 3.  Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome.

Authors:  M T Keogan
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

Review 4.  Gastrointestinal manifestations of Behçet's disease.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

Review 5.  Similarities and differences between Behçet's disease and Crohn's disease.

Authors:  Veli Yazısız
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

6.  Mimicry and deception in inflammatory bowel disease and intestinal behçet disease.

Authors:  Erika L Grigg; Sunanda Kane; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

7.  Quantitative analysis of retinal microcirculation in optical coherence tomography angiography in cases with Behçet's disease without ocular involvement.

Authors:  Ayşegül Çömez; Abdullah Beyoğlu; Yalçın Karaküçük
Journal:  Int Ophthalmol       Date:  2019-03-15       Impact factor: 2.031

8.  Confusing untypical intestinal Behcet's disease: Skip ulcers with severe lower gastrointestinal hemorrhage.

Authors:  Zhen-Kai Wang; Hui Shi; Shao-Dong Wang; Jiong Liu; Wei-Ming Zhu; Miao-Fang Yang; Chan Liu; Heng Lu; Fang-Yu Wang
Journal:  World J Gastrointest Endosc       Date:  2014-01-16

9.  Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.

Authors:  Luca Cantarini; Giuseppe Lopalco; Antonio Vitale; Laura Coladonato; Donato Rigante; Orso Maria Lucherini; Giovanni Lapadula; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2014-04-15       Impact factor: 2.980

10.  Multiple perforations along the transverse colon as a rare presentation of intestinal Behcet's disease: a case report.

Authors:  Kemal Karakaya; Mustafa Comert; Gamze Numanoglu
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.